3 completed, 1 active not recruiting, 1 recruiting. 5 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Active not recruiting 1, Recruiting 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
Follow Chronic Phase Chronic Myeloid Leukemia: new trials by email Literature Review of Chronic Phase Chronic Myeloid Leukemia trials Research Report on Chronic Phase Chronic Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors Ponatinib - Acute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | Incyte Biosciences International Sàrl | 70 | 2020-01-29 | 2026-10-09 |
| Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors Ruxolitinib, BCR-ABL Tyrosine Kinase Inhibitor (TKI) - Chronic Phase Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, Chronic Phase | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 24 | 2019-11-19 | 2026-04-02 |
| Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response Dasatinib - Chronic Phase Chronic Myeloid Leukemia | Phase 2 | Completed | Bristol-Myers Squibb | 84 | 2014-01-22 | 2022-11-03 |
| Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia Nilotinib, Ruxolitinib - Chronic Phase Chronic Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Completed | University Health Network, Toronto | 4 | 2013-08-01 | 2020-11-02 |
| Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib Imatinib, Dasatinib - Chronic Phase Chronic Myeloid Leukemia | Phase 2 | Completed | Bristol-Myers Squibb | 262 | 2012-09-12 | 2023-06-22 |
Leukemia, Myeloid, Chronic-Phase (5) · Blast Crisis (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Leukemia, Myeloid, Accelerated Phase (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Leukemia (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1)
Bone Marrow Diseases (5) · Chronic Disease (5) · Disease Attributes (5) · Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5) · Leukemia, Myeloid (5) · Myeloproliferative Disorders (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Leukemia (4) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3) · Carcinogenesis (2) · Cell Transformation, Neoplastic (2)
Dasatinib (2) · ruxolitinib (2) · Imatinib Mesylate (1) · nilotinib (1) · ponatinib (1)
Bristol-Myers Squibb (2) · H. Lee Moffitt Cancer Center and Research Institute (1) · Incyte Biosciences International Sàrl (1) · University Health Network, Toronto (1)
Canada (3) · France (3) · Italy (3) · Spain (3) · United States (3) · Belgium (2) · Argentina (1) · Austria (1) · Brazil (1) · China (1) · Czechia (1) · Germany (1) · Hungary (1) · Netherlands (1) · Poland (1)
Dennis Kim, MD/PhD (1) · Javier Pinilla-Ibarz, MD, PhD (1) · Mohammed-El-Amine Bensmaine, MD (1)
2018 (1), 2023 (1)